Evaluating a CytoSorb Score in Septic Shock
Launched by KLINIKUM EMDEN · Jun 5, 2019
Trial Information
Current as of June 02, 2025
Completed
Keywords
ClinConnect Summary
The primary effects of CytoSorb therapy, are, among many others, an improvement in hemodynamics, metobolism, and capillary integrity, with effects of adsorption seeming to reach far beyond mere cytokine adsorption.
Clinically, several publications have shown that certain patient populations benefit most from adjuvant CytoSorb treatment.
In a case series from the investigators department, they examined the effects of CytoSorb as an adjunctive therapy on hemodynamics and on clinically relevant outcome parameters in 26 patients with septic shock and the indication for renal replacement thera...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • septic shock according Sepsis 3 criteria
- Exclusion Criteria:
- • no data available, no icu treatment
About Klinikum Emden
Klinikum Emden is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. With a strong focus on collaboration and excellence, the facility engages in a wide range of studies across various medical disciplines, leveraging state-of-the-art technology and a multidisciplinary team of experts. Klinikum Emden is committed to ensuring the highest ethical standards and regulatory compliance while contributing to the development of new therapies and treatment protocols that enhance health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Emden, Lower Saxony, Germany
Patients applied
Trial Officials
Klaus Kogelmann, MD
Principal Investigator
head of department
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials